Lipocine (LPCN) Assets (2011 - 2025)
Lipocine's (LPCN) quarterly Assets came in at $17.0 million in Q4 2025, down 24.45% YoY from $22.5 million in Q4 2024, and up 5.8% on a QoQ basis from $16.1 million in Q3 2025.
Lipocine (LPCN) Assets (2011 - 2025) Analysis & Trends
Lipocine (LPCN) has 15 years of Assets data on file, last reported at $17.0 million in Q4 2025.
- Quarterly Assets fell 24.45% year-over-year to $17.0 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $17.0 million (down 24.45% YoY) and the FY2025 annual result came in at $17.0 million, down 24.45% from the prior year.
- Assets advanced to $17.0 million in Q4 2025, from $16.1 million in the prior quarter.
- In the past five years, Assets ranged from a high of $52.5 million in Q4 2021 to a low of $16.1 million in Q3 2025.
- A 5-year average of $31.7 million and a median of $28.0 million in 2023 frame the typical range for Assets.
- Annual changes were most pronounced in 2021 — Assets soared 140.93% — and 2023, when it slumped 38.73%.
- Tracing LPCN's Assets over 5 years: stood at $52.5 million in 2021, then fell by 28.47% to $37.5 million in 2022, then tumbled by 38.73% to $23.0 million in 2023, then slipped by 2.13% to $22.5 million in 2024, then decreased by 24.45% to $17.0 million in 2025.
- The last three Assets figures came in at $17.0 million (Q4 2025), $16.1 million (Q3 2025), and $18.6 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.47 Bn | 131.61 Bn | 2.84 Bn | 27.42 Bn |
| 2 | Regeneron Pharmaceuticals | 86.36 Bn | 78.37 Bn | 3.93 Bn | 41.73 Bn |
| 3 | Argenx Se | 65.16 Bn | 59.98 Bn | 1.37 Bn | 10.03 Bn |
| 4 | Moderna | 58.99 Bn | 53.85 Bn | 52.00 Mn | 10.96 Bn |
| 5 | BeOne Medicines | 42.08 Bn | 36.98 Bn | 1.53 Bn | 9.18 Bn |
| 6 | Alnylam Pharmaceuticals | 31.74 Bn | 28.43 Bn | 992.69 Mn | 5.56 Bn |
| 7 | BioNTech SE | 28.01 Bn | 9.61 Bn | 668.28 Mn | 25.60 Bn |
| 8 | Insmed | 27.50 Bn | 26.34 Bn | 358.27 Mn | 2.10 Bn |
| 9 | Royalty Pharma | 27.28 Bn | 26.45 Bn | - | 19.82 Bn |
| 10 | Lipocine | 11.37 Mn | -12.54 Mn | - | 17.01 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 17.01 Mn |
| Sep 30, 2025 | 16.07 Mn |
| Jun 30, 2025 | 18.58 Mn |
| Mar 31, 2025 | 20.50 Mn |
| Dec 31, 2024 | 22.51 Mn |
| Sep 30, 2024 | 20.70 Mn |
| Jun 30, 2024 | 23.03 Mn |
| Mar 31, 2024 | 25.45 Mn |
| Dec 31, 2023 | 23.00 Mn |
| Sep 30, 2023 | 24.75 Mn |
| Jun 30, 2023 | 30.48 Mn |
| Mar 31, 2023 | 34.02 Mn |
| Dec 31, 2022 | 37.54 Mn |
| Sep 30, 2022 | 39.42 Mn |
| Jun 30, 2022 | 42.19 Mn |
| Mar 31, 2022 | 47.60 Mn |
| Dec 31, 2021 | 52.48 Mn |
| Sep 30, 2021 | 40.39 Mn |
| Jun 30, 2021 | 47.18 Mn |
| Mar 31, 2021 | 50.58 Mn |